Bron A
Service d'Ophtalmologie, CHU de Dijon, Hôpital Général, 3, rue du Faubourg Raines, B.P. 1519, 21033 Dijon Cedex, France.
J Fr Ophtalmol. 2004 Sep;27 Spec No 2:2S33-2S38.
To collect data reflecting the current knowledge on the interactions of medical antiglaucomatous therapy and circadian variations.
Review of the available literature published on this topic in common electronic databases.
The IOP-reducing effect of a molecule throughout the day depends on many parameters and still remains poorly investigated. It is well known that beta-blockers have a poor efficacy at night, while prostaglandins prevent nocturnal IOP variations because of their original mechanism.
The lack of a 24-hour IOP recording device limits our ability to track the effect of antiglaucomatous drugs over 24 hours, an important point because these antiglaucomatous drugs vary in terms of their capacity to reduce IOP over a 24-hour period.
Assessing the effect of antiglaucomatous therapy on a 24-hour basis remains very difficult. However, in the next few Years, this could become an emerging focus point in the management of glaucoma.
收集反映当前关于抗青光眼药物治疗与昼夜节律变化相互作用的知识的数据。
回顾常见电子数据库中关于该主题发表的现有文献。
一种分子在一天中的降眼压效果取决于许多参数，目前对此研究仍较少。众所周知，β受体阻滞剂在夜间疗效不佳，而前列腺素因其独特机制可预防夜间眼压变化。
缺乏24小时眼压记录设备限制了我们追踪抗青光眼药物24小时效果的能力，这一点很重要，因为这些抗青光眼药物在24小时内降低眼压的能力各不相同。
基于24小时评估抗青光眼治疗的效果仍然非常困难。然而，在未来几年，这可能会成为青光眼治疗中一个新的焦点。
